- Home
- WST vs EQR Comparison
WST vs EQR Comparison
Compare WST & EQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WST | EQR |
|---|---|---|
| Founded | 1923 | 1993 |
| Country | United States | United States |
| Employees | 10800 | N/A |
| Industry | Medical/Dental Instruments | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.8B | 25.5B |
| IPO Year | 2004 | 1994 |
Fundamental Metrics
Financial Performance| Metric | WST | EQR |
|---|---|---|
| Price | $365.55 | $69.57 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 13 |
| Target Price | ★ $325.86 | $69.63 |
| AVG Volume (30 Days) | 674.9K | ★ 2.8M |
| Earning Date | 04-23-2026 | 04-28-2026 |
| Dividend Yield | 0.30% | ★ 4.29% |
| EPS Growth | 1.49 | ★ 8.09 |
| EPS | ★ 1.92 | 0.24 |
| Revenue | ★ $2,886,900,000.00 | $2,701,075,000.00 |
| Revenue This Year | $6.76 | $4.07 |
| Revenue Next Year | $6.22 | $3.14 |
| P/E Ratio | ★ $190.59 | $290.63 |
| Revenue Growth | 1.95 | ★ 4.76 |
| 52 Week Low | $206.80 | $57.57 |
| 52 Week High | $367.66 | $69.76 |
Technical Indicators
Market Signals| Indicator | WST | EQR |
|---|---|---|
| Relative Strength Index (RSI) | 78.53 | 66.06 |
| Support Level | $253.53 | $58.62 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 7.33 | 1.26 |
| MACD | 2.68 | 0.29 |
| Stochastic Oscillator | 95.80 | 100.00 |
Price Performance
Historical ComparisonAbout WST West Pharmaceutical Services Inc.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
About EQR Equity Residential of Beneficial Interest
Equity Residential owns a portfolio of 312 apartment communities with over 85,000 units and is developing two additional properties with 665 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.